Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.





Power3 Medical Products Inc (OTCBB:PWRM.OB) signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

PWRM strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

More about PWRM at:

GlobalOptions Group, Inc. (NasdaqCM:GLOI) a leading provider of risk mitigation and management services, announced on October 28, 2010 that its Board of Directors authorized the repurchase of up to $3 million of the Company’s common stock over a period of 18 months, at such times, amounts and prices as the Company shall deem appropriate. The Company intends to initiate an open market share repurchase program as soon as practicable to repurchase up to $3 million of the Company’s common stock. The repurchases may take place in the open market or in privately negotiated transactions, and may be made under a Rule 10b5-1 plan.
GlobalOptions Group, Inc. provides risk mitigation and management services to government entities, Fortune 1,000 corporations, and high net-worth and high-profile individuals worldwide.

AVI Biopharma, Inc. (NasdaqGM:AVII) a developer of RNA-based therapeutics, announced on October 27, 2010 three key leadership appointments supporting the expansion of its drug discovery, research and development capabilities. Graham Johnson, Ph.D., has joined AVI as its Senior Vice President, Preclinical Development and Research. Additionally, Patrick Iversen, Ph.D., has been appointed Senior Vice President of Research and Innovation, and Ryszard Kole, Ph.D., has been appointed Senior Vice President and an AVI Distinguished Scientist. With these appointments, AVI seeks to further accelerate its leading scientific expertise and focus efforts on continuing to expand and fully leverage its technology platforms to discover and develop innovative RNA-based therapeutics for rare and infectious diseases.
AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology.

Trident Microsystems Inc. (NasdaqGS:TRID) announced financial results for its third quarter ended September 30, 2010. Net revenues of $176.6 million, which compares with $171.6 million in the prior sequential quarter and $31.1 million in the quarter ended Sept. 30, 2009. On a generally accepted accounting principles ("GAAP") basis, the company reported a net loss for the quarter of $17.5 million, or $0.10 per share. Non-GAAP net loss for the quarter was $0.0 million, or $0.00 per share.
Trident Microsystems, Inc. provides high-performance multimedia semiconductor solutions for the digital home entertainment market. It designs, develops, and markets integrated circuits (ICs), and related software for processing, displaying, and transmitting high quality audio, graphics, and images in home consumer electronics applications, such as digital TVs, PC and analog TVs, and set-top boxes.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).